Drug Trial Radar · NCT03155191
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
Last checked: Nov 20, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
21
Planned (sponsor's estimate)
Start
Jun 1, 2017
Primary completion
Mar 31, 2035
Study completion Mar 31, 2035
Sponsor
- Lead sponsor
- Takara Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- May 16, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety (P-I), pharmacokinetics and anti-tumor effect of immunotherapy of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR) (TBI-1501) for relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.
Conditions
- Lymphoblastic Leukemia, Acute Adult
Interventions
TBI-1501Biological
Phase-I portion: Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\^5 cells/kg, cohort 1: 1×10\^6 cells/kg, cohort 2: 3×10\^6 cells/kg). Phase-II portion: Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase-I portion: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: One year
- Phase-II portion: Anti-tumor effect (CR+CRi rate)Time frame: 56 days
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Akita University Hospital
Akita, Akita, Japan
University Of Fukui Hospital
Yoshida, Fukui, Japan
Kyushu University Hospital
Higashiku, Fukuoka, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
Mie University Hospital
Tsu, Mie-ken, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Okayama University Hospital
Okayama, Okayama-ken, Japan
Jichi Medical University hospital
Shimotsuke-shi, Tochigi, Japan
Cancer Institute Hospital Of JFCR
Kōto, Tokyo, Japan
The Institute of Medical Science, The University of Tokyo
Minato-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.